IDXG
What one share of Interpace Biosciences holds
Surgical and Medical Instruments and Apparatus
We are a company that provides esoteric molecular diagnostic testing and pathology services to aid physicians in their evaluation of cancer risk in patients with indeterminate biopsies and a perceived risk of cancer from clinical features.
Interpace Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.32 |
|---|---|
| Profit | $0.89 |
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | $0.15 |
| Cash and investments | $0.10 |
| Book value | $0.84 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $72.05 | −$121.16 | — | −$41.89 | — | −$46.46 |
| 2018 | $7.78 | −$4.51 | $0.16 | −$3.24 | — | $5.38 |
| 2019 | $6.47 | −$7.25 | $0.04 | −$5.10 | — | −$1.14 |
| 2020 | $8.04 | −$7.32 | $0.39 | −$3.86 | — | −$7.17 |
| 2021 | $1.98 | −$3.61 | $0.09 | −$2.19 | — | −$10.11 |
| 2022 | $1.34 | −$5.18 | $0.08 | −$1.89 | — | −$13.52 |
| 2023 | $9.17 | $0.45 | $0.11 | $0.76 | — | −$12.76 |
| 2024 | $2.98 | $0.40 | $0.06 | $0.24 | — | — |
| 2025 | $1.40 | $0.89 | $0.01 | $0.20 | — | $5.05 |